Iterum Therapeutics plc Ordinary Share (ITRM) Stock Price

ITRMStock

$0.00+76.25%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta1.48

ITRM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-107.58%

Price vs S&P 500 (4W)-99.37%

VGM Score45.78

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)0.39x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-106.83%

Net Profit Margin (TTM)-2302.31%

EPS (TTM)$-0.75

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-0.75

EPS (Annual)$-1.25

ROI (Annual)-78.68%

Net Profit Margin (5Y Avg)-40639.07%

Cash / Share (Quarterly)$0.22

ROA (Last FY)-55.56%

EBITD / Share (TTM)$-0.55

ROE (5Y Avg)-116.44%

Operating Margin (TTM)-1982.31%

Cash Flow / Share (Annual)$-0.84

P/B Ratio0.22x

P/B Ratio (Quarterly)2.92x

Net Income / Employee (Annual)$-2,777,800

EV / Revenue (TTM)60.20x

Net Interest Coverage (TTM)-0.37x

ROA (TTM)-74.63%

EPS Incl Extra (Annual)$-1.25

Current Ratio (Annual)1.39x

Quick Ratio (Quarterly)1.80x

3-Month Avg Trading Volume10.88M

52-Week Price Return76.25%

Revenue / Employee (TTM)$43,300

Tangible BV / Share (Quarterly)$0.23

P/S Ratio (Annual)18.65x

Asset Turnover (Annual)0.00x

52-Week High$0.80

Operating Margin (5Y Avg)-31510.38%

EPS Excl Extra (Annual)$-1.25

CapEx CAGR (5Y)-36.90%

Tangible BV CAGR (5Y)-7.85%

26-Week Price Return-99.97%

Quick Ratio (Annual)1.36x

13-Week Price Return-99.43%

Total Debt / Equity (Annual)1.02x

Current Ratio (Quarterly)2.13x

Enterprise Value$23.48M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-45.24%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-256725.00%

Cash / Share (Annual)$0.75

3-Month Return Std Dev670.71%

Net Income / Employee (TTM)$-2,995,400

ROE (Last FY)-158.68%

Net Interest Coverage (Annual)-3.44x

EPS Basic Excl Extra (Annual)$-1.25

Total Debt / Equity (Quarterly)5.76x

EPS Incl Extra (TTM)$-0.75

ROI (TTM)-74.22%

P/S Ratio (TTM)1.91x

Pretax Margin (5Y Avg)-40344.92%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.09

Price vs S&P 500 (52W)55.68%

Year-to-Date Return-99.97%

5-Day Price Return-99.63%

EPS Normalized (Annual)$-1.25

ROA (5Y Avg)-105.37%

Net Profit Margin (Annual)-257825.00%

Month-to-Date Return-99.80%

Cash Flow / Share (TTM)$-2.30

EBITD / Share (Annual)$-1.25

Operating Margin (Annual)-255050.00%

LT Debt / Equity (Annual)1.02x

ROI (5Y Avg)-84.30%

LT Debt / Equity (Quarterly)5.76x

EPS Basic Excl Extra (TTM)$-0.75

P/TBV (Quarterly)3.30x

P/B Ratio (Annual)0.37x

Pretax Margin (TTM)-2268.46%

Book Value / Share (Annual)$2.22

Price vs S&P 500 (13W)-103.64%

Beta1.48x

Revenue / Share (TTM)$0.01

ROE (TTM)-216.35%

52-Week Low$0.00

vGradeB

mGradeD

vgmGradeC

ITRM Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ITRMIterum Therapeutics plc Ordinary Share	B	—	D	1.9x	—	—	—	$0.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Iterum Therapeutics plc Ordinary Share

Iterum Therapeutics is a pharmaceutical company commercializing Orlynvah, an oral-branded penem antibiotic approved in the United States for treating complicated urinary tract infections. Orlynvah has the potential to be the first and only oral and intravenous branded penem available globally. The company targets drug-resistant bacterial infections, addressing a significant unmet medical need.